The Health Products and Food Branch is consulting on its revised cost recovery framework, which covers fees for the regulation, licencing, and post market surveillance of drugs, medical devices and natural health products.
These consultations are a necessary step in the HPFB Cost Recovery Initiative. The CRI aims to address the current and future needs of the Branch to build a comprehensive, responsive and appropriate platform for longer term financial sustainability of the Branch regulatory activities.
The consultation aims to inform all stakeholders of the changes being made to the cost recovery framework (and the rationale behind them), to obtain information on the expected business impact of the framework, to obtain input on more general concerns about the framework, and to solicit suggestions to perfect the framework.
|